Pneumocystis pneumonia in children receiving chemotherapy | Zendy

Prasad Pinki | Zendy; Nania Joseph J. | Zendy; Shankar Sadhna M. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Pneumocystis pneumonia in children receiving chemotherapy

Author(s) -

Prasad Pinki,

Nania Joseph J.,

Shankar Sadhna M.

Publication year - 2008

Publication title -

pediatric blood and cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.116

H-Index - 105

eISSN - 1545-5017

pISSN - 1545-5009

DOI - 10.1002/pbc.21202

Subject(s) - medicine , pentamidine , dapsone , chemotherapy , pneumonia , immunosuppression , trimethoprim , pneumocystis carinii , complication , sulfamethoxazole , cancer chemotherapy , pediatrics , blood cancer , pneumocystis pneumonia , chemoprophylaxis , surgery , cancer , antibiotics , pneumocystis jirovecii , immunology , microbiology and biotechnology , biology

Pneumocystis pneumonia (PCP) is a serious complication of chemotherapy‐induced immunosuppression. Trimethoprim‐sulfamethoxazole (TMP‐SMZ) given twice daily, 3 days every week is considered the best form of prophylaxis for PCP. We evaluated PCP prophylaxis in all children up to 18 years of age undergoing cancer chemotherapy over a 2‐year period. Four children were diagnosed with PCP over 24 months. Two of 12 children on intravenous pentamidine, 1 of 143 on TMP‐SMZ and 1 of 36 on dapsone for PCP prophylaxis developed PCP. Intravenous pentamidine may not be as effective as previously considered and should be used with caution. Pediatr Blood Cancer 2008;50:896–898. © 2007 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research